Tarsus Pharmaceuticals (TARS) FCF Margin (2021 - 2026)

Tarsus Pharmaceuticals' FCF Margin history runs 6 years deep, the most recent figure standing at 18.8% for Q1 2026.

• In Q1 2026, FCF Margin rose 761.0% year-over-year to 18.8%; the TTM figure through Mar 2026 stood at 6.0% (up 2289.0% YoY), while the FY2025 annual figure was 4.94%, up 4130.0% from the prior year.
• FCF Margin was 18.8% for Q1 2026 at Tarsus Pharmaceuticals, down from 8.55% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 12.72% in Q3 2025 to a low of 2865.86% in Q1 2022.
• Historically, FCF Margin has averaged 414.02% across 5 years, with a median of 33.51% in 2024.
• Biggest YoY gain for FCF Margin was 338922 bps in 2022; the steepest drop was 283006 bps in 2022.
• A 5-year view of FCF Margin shows it stood at 105.16% in 2022, then sank by 176 bps to 290.36% in 2023, then jumped by 88 bps to 33.51% in 2024, then soared by 126 bps to 8.55% in 2025, then slumped by 320 bps to 18.8% in 2026.
• The last three FCF Margin figures came in at 18.8% (Q1 2026), 8.55% (Q4 2025), and 12.72% (Q3 2025), per Business Quant data.